Tarsus Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Tarsus Pharmaceuticals generated $61.2 million of operating cash flow and spent $4.1 million on capital expenditures. That left free cash flow of $57.2 million, a free-cash-flow margin of 32.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -18.55M | -6.97M | -8.37M | -12.59M | -20.34M | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M | -41.90M | -39.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 800.00K | 197.00K | 202.00K | 200.00K | 200.00K | 220.00K | 192.00K | 200.00K | 100.00K | 170.00K | 247.00K | 200.00K |
| Stock-Based Compensation | 13.29M | 11.97M | 14.31M | 12.24M | 8.23M | 6.93M | 7.40M | 7.42M | 7.48M | 5.52M | 5.48M | 5.25M |
| Change in Working Capital | 19.51M | -30.48M | -12.97M | -14.25M | 2.92M | -15.75M | -17.37M | -282.00K | -336.00K | -14.19M | -14.35M | -5.38M |
| Operating Cash Flow | 61.22M | -24.65M | 19.33M | 18.26M | -29.39M | -20.65M | -22.18M | -8.65M | -14.40M | -37.79M | -39.34M | -32.36M |
| Capital Expenditures | -4.07M | -5.82M | -6.36M | -1.91M | -1.00M | -590.00K | -72.00K | -282.00K | -1.04M | -174.00K | 0 | -375.00K |
| Investing Cash Flow | 37.88M | -58.56M | 49.27M | -4.74M | -51.70M | -34.94M | -59.57M | 3.13M | -40.52M | -102.22M | 17.85M | 47.37M |
| Debt Issued | — | — | 0 | 0 | — | — | 0 | 0 | 75.00M | 0 | 0 | 5.00M |
| Financing Cash Flow | 3.30M | 1.20M | 2.31M | 2.56M | 1.95M | 136.56M | 2.93M | 639.00K | 42.32M | 108.77M | 19.76M | 104.89M |
| Net Change in Cash | 102.40M | -82.01M | 70.92M | 16.08M | -79.14M | 80.97M | -78.83M | -4.88M | -12.61M | -31.24M | -1.73M | 119.90M |
| Free Cash Flow | 57.15M | -30.47M | 12.97M | 16.35M | -30.39M | -21.24M | -22.25M | -8.93M | -15.44M | -37.96M | -39.34M | -32.74M |
This table shows 12 quarterly periods of Tarsus Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a cash flow statement?